Cargando…
Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations
Introduction and Objective: Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine...
Autores principales: | Godói, Isabella P., Santos, André S., Reis, Edna A., Lemos, Livia L. P., Brandão, Cristina M. R., Alvares, Juliana, Acurcio, Francisco A., Godman, Brian, Guerra Júnior, Augusto A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288336/ https://www.ncbi.nlm.nih.gov/pubmed/28210223 http://dx.doi.org/10.3389/fphar.2017.00041 |
Ejemplares similares
-
Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning
por: Dorigatti, I., et al.
Publicado: (2018) -
Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
por: Laydon, Daniel J, et al.
Publicado: (2021) -
Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America
por: Carpp, Lindsay N., et al.
Publicado: (2020) -
Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017) -
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
por: Forrat, Rémi, et al.
Publicado: (2021)